C-reactive protein and coronary artery disease;C-Reaktif Protein ve Koroner Arter Hastaliǧi

Anadolu Kardiyoloji Dergisi

Volumn 4, Issue 3, 2004, Pages 203-204

  Acartürk, Esmeray ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR RISK; CHRONIC DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; EDITORIAL; FORCED EXPIRATORY VOLUME; HUMAN; HYPERLIPIDEMIA; LOGISTIC REGRESSION ANALYSIS; MEDICAL SOCIETY; STABLE ANGINA PECTORIS; STATISTICAL ANALYSIS;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ARTERIOSCLEROSIS; HUMANS;

EID: 4644287785     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (19)

1. Auer J, Berent R, Lassnig E, Eber B. C-reactive protein and coronary artery disease. Jpn Heart J 2002; 43: 607-19.
2. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol 1990; 65: 168-72.
3. Yamashita H, Shimada K, Seki E, Mokuno H, Daida H. Concentrations of interleukins, interferon, and C-reactive protein in stable and unstable angina pectoris. Am J Cardiol 2003; 91: 133-6.
4. Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MB, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk for coronary events in stable and unstable angina. Lancet 1997; 349: 462-6.
5. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-65.
6. Auer J, Rammer M, Berent R, Weber T, Lassnig E, Eber B. Relation of C-reactive protein levels to presence, extent, and severity of angiographic coronary artery disease. Indian Heart J 2002; 54: 284-8.
7. Heinrich J, Schulte H, Schönfeld R, Kohler E, Assmann G. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemostas 1995; 73: 374-8.
8. Mendall MA, Strachan DP, Butland BK, et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 2000; 21: 1584-90.
9. Türkoǧlu EI, Gürgür C, Zoghi M, Türkoǧ lu C. Kararli anginasi olan ve efor testi pozitif bulunan ayaktan hastalarda serum C-reaktif protein düzeyleri ile koroner arter hastaliǧi ilşkisi. Anadolu Kardiyol Derg 2004; 4: 199-202.
10. Shah SH, Newby LK. C-reactive protein: A novel marker of cardiovascular risk. Cardiology in Review 2003; 11: 169-79.
11. Pearson TA, Mensah GA, Alexander RW, et al. Markers of imflammation and cardiovascular disease: Application to clinical and public health practice: A statement for health-care professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
12. Dev D, Wallace E, Sankaran R, Cunniffe J, et al. Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir Med 1998; 92: 664-7.
13. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles S. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959-65.
14. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998; 98: 839-44.
15. Cushman M, Legault C, Barret-Connor E, et al. Effect of postmenopausal hormones on iflammation-sensitive proteins: Postmenopausal Estrogen/Progestin Interventions (PEPI) study. Circulation 1999; 100: 717-22.
16. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999; 100: 713-6.
17. Ylikorkala O, Evio S, Valimaki M, Tiitinen A. Effects of hormone therapy and alendronate on C-reactive protein, E-selectin, and sex hormone-binding globulin in osteoporotic women. Fertil Steril 2003; 80: 541-5.
18. Sümbüllüoǧlu K, Sümbüllüoǧlu V. Biyoistatistik. 9.Baski. Ankara: Hatiboǧlu Yayinevi; 2000.
19. Çapaci K. Tibbi Araştirmalarda Sik Kullanilan ̇Istatistik Yöntemler-1. Ege Fiz Tip Reh Derg 2000; 6: 27-35.